PAPER Alafuzoff I, Parkkinen L, Al-Sarraj S, Arzberger T, Bell J, Bodi I, Bogdanovic N, Budka H, Ferrer I, Gelpi E, Gentleman S, Giaccone G, Kamphorst W, King A, Korkolopoulou P, Kovács GG, Larionov S, Meyronet D, Monoranu C, Morris J, Parchi P, Patsouris E, Roggendorf W, Seilhean D, Streichenberger N, Thal DR, Kretzschmar H,
SEARCH RESULTS
330907 RESULTS
PAPER Golovko MY, Murphy EJ
Brain prostaglandin formation is increased by alpha-synuclein gene-ablation during global ischemia.
Neurosci Lett. 2008 Feb 27;432(3):243-7. PubMed: 18226447PAPER Nannenga BL, Zameer A, Sierks MR
Anti-oligomeric single chain variable domain antibody differentially affects huntingtin and alpha-synuclein aggregates.
FEBS Lett. 2008 Feb 20;582(4):517-22. PubMed: 18230361PAPER Parkkinen L, Hartikainen P, Alafuzoff I
Abundant glial alpha-synuclein pathology in a case without overt clinical symptoms.
Clin Neuropathol. 2007 Nov-Dec;26(6):276-83. PubMed: 18232593PAPER Lynch SM, Zhou C, Messer A
An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity.
J Mol Biol. 2008 Mar 14;377(1):136-47. PubMed: 18237741PAPER Kowalik-Jankowska T, Rajewska A, Jankowska E, Grzonka Z
Products of Cu(II)-catalyzed oxidation of alpha-synuclein fragments containing M1-D2 and H50 residues in the presence of hydrogen peroxide.
Dalton Trans. 2008 Feb 14;(6):832-8. PubMed: 18239841PAPER Kawasaki S, Watanabe S, Kimura S, Fujita R, Ochiai J, Sasaki K
Regulation of dopamine-induced Na+ current response by small G-protein RhoB or C and phospholipase D in Aplysia neurons.
Neurosci Res. 2008 Feb;60(2):147-55. PubMed: 18242417PAPER Botella JA, Bayersdorfer F, Schneuwly S
Superoxide dismutase overexpression protects dopaminergic neurons in a Drosophila model of Parkinson's disease.
Neurobiol Dis. 2008 Apr;30(1):65-73. PubMed: 18243716PAPER Devi L, Raghavendran V, Prabhu BM, Avadhani NG, Anandatheerthavarada HK
Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain.
J Biol Chem. 2008 Apr 4;283(14):9089-100. PubMed: 18245082PAPER Bar-On P, Crews L, Koob AO, Mizuno H, Adame A, Spencer B, Masliah E
Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease.
J Neurochem. 2008 Jun;105(5):1656-67. PubMed: 18248604PAPER Boas JF, Drew SC, Curtain CC
Applications of electron paramagnetic resonance to studies of neurological disease.
Eur Biophys J. 2008 Mar;37(3):281-94. PubMed: 18256819PAPER Yoon J, Park J, Jang S, Lee K, Shin S
Conformational characteristics of unstructured peptides: alpha-synuclein.
J Biomol Struct Dyn. 2008 Apr;25(5):505-15. PubMed: 18282005PAPER Attems J, Jellinger KA
The dorsal motor nucleus of the vagus is not an obligatory trigger site of Parkinson's disease.
Neuropathol Appl Neurobiol. 2008 Aug;34(4):466-7. PubMed: 18282157PAPER George S, van den Buuse M, San Mok S, Masters CL, Li QX, Culvenor JG
Alpha-synuclein transgenic mice exhibit reduced anxiety-like behaviour.
Exp Neurol. 2008 Apr;210(2):788-92. PubMed: 18295208PAPER Benarroch EE, Schmeichel AM, Low PA, Sandroni P, Parisi JE
Loss of A5 noradrenergic neurons in multiple system atrophy.
Acta Neuropathol. 2008 Jun;115(6):629-34. PubMed: 18297292Current Filters
No filters selected